tbuckley/cabot-search huggingface dataset:
Efficacy of segmental re-examination of proximal colon for adenoma detection during colonoscopy: a randomized controlled trial
Authors: Chuan-Guo Guo, Feifei Zhang, Rui Ji, Yueyue Li, Lixiang Li, Xiu-Li Zuo, Yan-Qing Li
Journal: Endoscopy (2017)

<b>Background and study aims </b>Interval colorectal cancers detected after screening colonoscopy are more likely to be associated with missed lesions in the proximal colon. The aim of this study was to determine whether segmental re-examination of the proximal colon could increase the proximal adenoma detection rate (ADR) and to evaluate the time-effectiveness of this approach. <b>Patients and methods </b>Patients undergoing colonoscopy were recruited into the prospective randomized controlled study. They were randomly assigned to the segmental re-examination group, in which the proximal colon was examined twice segmentally, and a control group in which the withdrawal time was extended (EWT). Detection rates were calculated and compared for all polyps and adenomas in both the proximal colon and the whole colon. Withdrawal times were recorded and compared. <b>Results </b>A total of 360 patients were included in the study (re-examination 178 vs. EWT 182). The proximal ADR in the re-examination group was higher than that in the EWT group (33.1 % vs. 23.6 %; <i>P</i> = 0.045). More proximal adenomas were detected per patient in the re-examination group (0.54 vs. 0.36; <i>P</i> = 0.048). The ADR of the whole colon was similar in the two groups. Proximal withdrawal time was also similar (re-examination 4.29 ± 1.23 minutes vs. EWT 4.34 ± 1.36 minutes; <i>P</i> = 0.74). In addition, there was no statistically significant difference in the total duration of the colonoscopy between the two groups. <b>Conclusions </b>Segmental re-examination of the proximal colon increased the proximal ADR and the number of proximal adenomas detected, and was accomplished easily and safely without increasing the overall examination time. Trial registration: ClinicalTrials.gov (NCT02581475)
Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.
Authors: Gaetano Corazzelli, Ferdinando Frigeri, Gianpaolo Marcacci, Cristina Becchimanzi, Gaetana Capobianco, Manuela Arcamone, Emanuela Morelli, Francesco Volzone, Filippo Russo, Antonio Pinto
Journal: Blood (2010)
Blocking microglial pannexin-1 channels alleviates morphine withdrawal in rodents
Authors: Nicole E Burma, Robert P Bonin, Heather Leduc-Pessah, Corey Baimel, Zoe F Cairncross, Michael Mousseau, Jhenkruthi Vijaya Shankara, Patrick L Stemkowski, Dinara Baimoukhametova, Jaideep S Bains, Michael C Antle, Gerald W Zamponi, Catherine M Cahill, Stephanie L Borgland, Yves De Koninck, Tuan Trang
Journal: Nature Medicine (2017)
R399H Mutated ETS Domain Leads to a Functional ETV6 Double-Knock-Out in Acute Leukemia and Completely Alters the Physiological Function of ETV6.
Authors: Heike Hennig, Frauke Hillmer, Annegret Becker, Martina Podleschny, Tobias Pukrop, Lorenz H. Truemper, Frank Griesinger
Journal: Blood (2004)
Membrane Remodeling By Pathogenic Antibodies Underlies Monocyte Activation in Heparin-Induced Thrombocytopenia
Authors: Izabella Andrianova, Vincent M Hayes, Daria Madeeva, Rustem I. Litvinov, Douglas B. Cines, Mortimer Poncz, John W. Weisel, Lubica Rauova
Journal: Blood (2015)
Screening for Syphilis Infection in Pregnancy: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement
Journal: Annals of Internal Medicine (2009)

Description: Update of the 2004 U.S. Preventive Services Task Force statement about screening for syphilis in pregnancy. Methods: The U.S. Preventive Services Task Force did a targeted literature search for evidence on the benefits of screening, the harms of screening, and the harms of treatment of syphilis with penicillin during pregnancy. Recommendation: Screen all pregnant women for syphilis infection. (Grade A recommendation.)
Continuous Glucose Monitoring in Patients With Type 1 Diabetes Taking Insulin Injections
Authors: Mayer B. Davidson
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer
Authors: Xiaoxue Zhang, Dan Liu, Mengchen Li, Canhui Cao, Dongyi Wan, Bixin Xi, Wenqian Li, Jiahong Tan, Ji Wang, Zhongcai Wu, Ding Ma, Qinglei Gao
Journal: Journal of Hematology & Oncology (2017)

Epigenetics has been known to play a critical role in regulating the malignant phenotype. This study was designed to examine the expression of DOT1L (histone 3 lysine 79 methyltransferase) and H3K79 methylation in normal ovarian tissues and ovarian tumors and to explore the function of DOT1L and its underline mechanisms in ovarian cancer. The expression of DOT1L and H3K79 methylation in 250 ovarian tumor samples and 24 normal ovarian samples was assessed by immunohistochemistry. The effects of DOT1L on cell proliferation in vitro were evaluated using CCK8, colony formation and flow cytometry. The DOT1L-targeted genes were determined using chromatin immune-precipitation coupled with high-throughput sequencing (ChIP-seq) and ChIP-PCR. Gene expression levels were measured by real-time PCR and immunoblotting. The effects of DOT1L on tumor growth in vivo were evaluated using an orthotopic ovarian tumor model. DOT1L expression and H3K79 methylation was significantly increased in malignant ovarian tumors. High DOT1L expression was associated with International Federation of Gynecology and Obstetrics (FIGO) stage, histologic grade, and lymphatic metastasis. DOT1L was an independent prognostic factor for the overall survival (OS) and progression-free survival (PFS) of ovarian cancer, and higher DOT1L expression was associated with poorer OS and PFS. Furthermore, DOT1L regulates the transcription of G1 phase genes CDK6 and CCND3 through H3K79 dimethylation; therefore, blocking DOT1L could result in G1 arrest and thereby impede the cell proliferation in vitro and tumor growth in vivo. Our findings first demonstrate that DOT1L over-expression has important clinical significance in ovarian cancer and also clarify that it drives cell cycle progression through transcriptional regulation of CDK6 and CCND3 through H3K79 methylation, suggesting that DOT1L might be potential target for prognostic assessment and therapeutic intervention in ovarian cancer.
Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes of Multiple Myeloma Patients Undergoing Autologous Transplantation – A Multicenter Analysis
Authors: Farrukh Awan, Salman Osman, Samith Thomas Kochuparambil, Scot Remick, Jame Abraham, Michael Craig, Anand P. Jillella, Sayed Mehdi Hamadani
Journal: Blood (2010)
Bio-Distribution of Recombinant Factor VIIa: A Possible Explanation for the Hemostatic Effect of rFVIIa in Prophylaxis.
Authors: Ramakrishnan Gopalakrishnan, Ulla Hedner, Samit Ghosh, Ramesh Nayak, Usha Pendurthi, L. Vijaya Mohan Rao
Journal: Blood (2009)
Commentary: The real problem is that electronic health records focus too much on billing
Authors: Jeanne Lenzer
Journal: BMJ (2017)

Advocates say that electronic health records increase patient safety through computerized prescriber order entry and integration of decision supports and guidelines. They also vastly increase opportunities for clinical research using “big data.”123

But critics, like Steven J Stack, the immediate past president of the American Medical Association (AMA), are unconvinced. Stack writes that electronic records “have so much potential, but frustrating government regulations have made them almost unusable,” adding that they were expected to “help facilitate patient engagement, reduce administrative burdens and promote exchange of data.” But those benefits, he said, “definitely” haven’t happened.4

A recent time-motion study sponsored by the AMA found that “For every hour physicians provide direct clinical face …
Erythropoietin Treatment Leads to Reduced Blood Glucose Levels and Body Mass: Insights From Murine Models.
Authors: Odelia Katz, Matthew Stuible, Nataliya Golishevski, Lilach Lifshitz, Michel Tremblay, Max Gassman, Howard S Oster, Moshe Mittelman, Drorit Neumann
Journal: Blood (2009)
Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk
Authors: Eliano P. Navarese, Michalina Kolodziejczak, Stefano De Servi
Journal: JAMA (2017)

To the Editor Dr Silverman and colleagues1 examined the relationship between lowering low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk reduction among different statin and nonstatin therapies. We think that further discussion about the statin therapeutic group is needed.
Intravenous Immunoglobulin Manufactured Using a Novel Caprylate and Chromatography-Based Method (IGIV-C, Gamunex®) Was Safe and Well Tolerated When Administered at an Increased Maximum Rate in Patients with Idiopathic Thrombocytopenic Purpura (ITP).
Authors: James B. Bussel, Kim Hanna
Journal: Blood (2004)
The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG.
Authors: Sabine Kayser, Konstanze Döhner, Jürgen Krauter, Daniela Späth, Silja Groner, Brigitte Schlegelberger, Gudrun Göhring, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk
Journal: Blood (2007)
Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): Second interim analysis of the Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib (GIDEON) study.
Authors: Jeff H. Geschwind, Riccardo Lencioni, Jorge A. Marrero, Alan Paul Venook, Sheng-Long Ye, Keiko Nakajima, Frank Cihon, Masatoshi Kudo
Journal: Journal of Clinical Oncology (2012)

317 Background: Locoregional treatments (LRTs) are widely used for HCC, with recognized regional variations but no universal standard. GIDEON is a global, prospective, non-interventional study evaluating sorafenib use in HCC patients (pts). The study allows evaluation of global trends in LRTs. Methods: &gt;3000 pts were enrolled in 39 countries (January 2009 to April 2011). Per protocol, the 2nd interim analysis was planned when ~1500 treated pts were followed for ≥4 months. Results: In the safety population analyzed (N=1571), 55% and 46% of pts received prior LRT and transarterial chemoembolization (TACE), respectively. Prior LRTs, including TACE, were more frequent in Asia-Pacific (AP) and Japan than in other regions. In pts who received TACE prior to the initiation of sorafenib therapy, the number of TACE treatments ≥3 was higher in AP and Japan than in other regions. Overall, 76% of pts received conventional TACE, and the most common TACE agent was doxorubicin. Median time from last TACE to initiation of sorafenib therapy was 3.1 months (Table). Worldwide, 8% of pts received TACE, concomitantly with sorafenib. The incidence of sorafenib-related adverse events/serious adverse events was generally similar in pts who did (70%/4%) or did not (64%/9%) receive concomitant TACE. Conclusions: The GIDEON study provides unique insight into the utilization of LRTs worldwide and contributes to better understanding and management of HCC pts. [Table: see text]
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
Authors: J.A. Pineda, L.E. Morano-Amado, R. Granados, J. Macías, F. Téllez, M. García-Deltoro, M.J. Ríos, A. Collado, M. Delgado-Fernández, M. Suárez-Santamaría, M. Serrano, C. Miralles-Álvarez, K. Neukam, J.C. Alados-Arboledas, H. Albendín, M.R. Alemán, M. del Mar Alonso, V. Asensi, M.J. Blanco, J. Borrallo, R. Cabo, Á. Camacho, M.F. Casas, Á. Castro, J. Cucurull, S. Cuéllar, F. Cuenca, I. de los Santos-Gil, C. Dueñas, E. Fernández, C. Galera, M.C. Gálvez, D. García, P. Geijo-Martínez, A. Gómez, J.L. Gómez, F. Gutiérrez, J. Hernández, J. Hernández, J. Llenas-García, M. Mancebo, M. Márquez, J.M. Martín, L. Martínez, R. Martínez-Álvarez, O. Martínez Madrid, M. del Mar Masiá, N. Merchante, D. Merino, P. Monje, R. Nuñez, M. Omar, E. Ortega, S. Padilla, C. Robledano, R. Pelazas, E. Pérez, I. Pérez-Camacho, M. Pérez-Pérez, B. Pernas, J.J. Portu, M. Raffo, L.M. Real, G. Reina, A. Rivero, A. Rivero-Juárez, A. Romero-Palacios, J. Portilla, P. Rubio, P. Ryan-Murua, P.S. de la Hoya, J. Santos, M. Serrano, C. Toyas, F. Vera-Méndez, A. Vergara, M.V. Hernández, D.V. García
Journal: Clinical Microbiology and Infection (2017)

The aim of this study was to determine the predictive capacity of response at treatment week (TW) 4 for the achievement of sustained virological response 12 weeks after the scheduled end of therapy date (SVR12) to treatment against hepatitis C virus (HCV) genotype 3 (GT3) infection with all-oral direct-acting antiviral (DAA) -based regimens.From a prospective multicohort study, HCV GT3-infected patients who completed a course of currently recommended DAA-based therapy at 33 Spanish hospitals and who had reached the SVR12 evaluation time-point were selected. TW4 HCV-RNA levels were categorized as target-not-detected (TND), below the lower limit of quantification (LLOQTD) and ≥LLOQ.A total of 123 patients were included, 86 (70%) received sofosbuvir/ daclatasvir±ribavirin, 27 (22%) received sofosbuvir/ ledipasvir/ ribavirin and 10 (8.1%) received sofosbuvir/ ribavirin, respectively. In all, 114 (92.7%) of the 123 patients presented SVR12 in an on-treatment approach, but nine (7.3%) patients relapsed, all of them had presented cirrhosis at baseline. In those who achieved TND, LLOQTD and ≥LLOQ, SVR12 was observed in 81/83 (98%; 95% CI 91.5%-99.7%), 24/28 (85.7%; 95% CI 67.3%-96%) and 9/12 (75%; 95% CI 42.8%-94.5%), respectively; p(linear association) 0.001. Corresponding numbers for subjects with cirrhosis were: 52/54 (96.3%; 95% CI 87.3%-95.5%), 14/18 (77.8%; 95% CI 52.4%-93.6%) and 7/10 (70%; 95% CI 34.8%-93.3%); p 0.004.TW4-response indicates the probability of achieving SVR12 to currently used DAA-based therapy in HCV genotype 3-infected individuals with cirrhosis. This finding may be useful to tailor treatment strategy in this setting.
Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).
Authors: Elizabeth R. Plummer, Emma Jane Dean, T.R. Jeffry Evans, Alastair Greystoke, Karin Herbschleb, Malcolm Ranson, Jennifer Brown, Yanqiong Zhang, Sharon Karan, John Pollard, Marina S. Penney, Mohammed Asmal, Scott Z. Fields, Mark R. Middleton
Journal: Journal of Clinical Oncology (2016)

2513 Background: ATR is a regulator of the cellular response to replication stress, where it signals DNA damage repair through the homologous recombination pathway.Many cancer cells depend on ATR to survive DNA damage. VX-970 is a potent, selective inhibitor of ATR with marked preclinical anticancer activity in combination with DNA-damaging chemotherapy in preclinical models. A multicenter phase I study of VX-970 in combination with Gem was performed. Methods: Patients (pts) with advanced solid tumors measurable by RECIST 1.1 received IV VX-970 in combination with Gem in a 3+3 dose-escalation design. Gem was administered on days 1 and 8 and VX-970 on days 2, 9 and 16 of each 21-day cycle. Results: 50 pts were treated (28 M/22 F), median age 62 yrs (range 28-79 yrs), ECOG PS 0/1: 15/35. Primary tumors were colorectal (n=15), NSCLC (n=6), breast (n=4), pancreatic (n=2) and other (n=23). Gr 3/4 treatment-related AEs occurred in 25 pts. Maximum tolerated dose was not reached. VX-970 exposure was approximately linear based on Cmax and AUC0-∞ ; terminal T1/2 was ≈16 h. Best response was PR in 4 pts (breast, NPC, NSCLC, and CUP). Two pts with cancers not typically responsive to chemotherapy had prolonged SD: PFS was 415 days (papillary ca) and >191 days (GIST). Exposures achieved at ≈90mg/m2 correlated to those showing maximum preclinical activity. In a parallel phase I study this dose blocked ATR activity by ≈75% in patient tumor biopsies. Preliminary data from a non-randomized comparison of cohorts 1-4 (VX-970 < 90mg/m2 with Gem 875 mg/m2) and 5-7 (VX-970 ≥ 90mg/m2 with Gem 500mg/m2) showed median PFS of 8.3 and 29.3 weeks, respectively. Conclusions: The recommended phase II dose is VX-970 210 mg/m2 and Gem 1000 mg/m2. Preliminary evidence of activity was observed. Studies in biomarker-defined NSCLC and SCLC are ongoing, as are additional studies with VX-970 and platinum in TNBC. Clinical trial information: NCT02157792.Cohort VX-970 dose (mg/m2) Gem dose (mg/m2) No. pts treated/No. pts evaluable for DLTs No. DLTs (DLT) 1 18 875 3/3 2 36 875 3/3 3 60 875 4/3 4 72 875 7/6 2 (gr 3 thrombocytopenia; gr 3 elevated ALT and fatigue) 5 90 500 6/6 1 (gr 3 elevated AST) 6 140 500 8/6 1 (gr 3 elevated AST and ALT, gr 2 elevated ALP) 7 210 500 3/3 8 210 750 3/3 9 210 875 7/6 10 210 1000 6/6
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
Authors: J Duell, M Dittrich, T Bedke, T Mueller, F Eisele, A Rosenwald, L Rasche, E Hartmann, T Dandekar, H Einsele, M S Topp
Journal: Leukemia (2017)

Blinatumomab can induce a complete haematological remission in patients in 46.6% with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) resulting in a survival benefit when compared with chemotherapy. Only bone marrow blast counts before therapy have shown a weak prediction of response. Here we investigated the role of regulatory T cells (Tregs), measured by CD4/CD25/FOXP3 expression, in predicting the outcome of immunotherapy with the CD19-directed bispecific T-cell engager construct blinatumomab. Blinatumomab responders (n=22) had an average of 4.82% Tregs (confidence interval (CI): 1.79–8.34%) in the peripheral blood, whereas non-responders (n=20) demonstrated 10.25% Tregs (CI: 3.36–65.9%). All other tested markers showed either no prediction value or an inferior prediction level including blast BM counts and the classical enzyme marker lactate dehydrogenase. With a cutoff of 8.525%, Treg enumeration can identify 100% of all blinatumomab responders and exclude 70% of the non-responders. The effect is facilitated by blinatumomab-activated Tregs, leading to interleukin-10 production, resulting in suppression of T-cell proliferation and reduced CD8-mediated lysis of ALL cells. Proliferation of patients' T cells can be restored by upfront removal of Tregs. Thus, enumeration of Treg identifies r/r ALL patients with a high response rate to blinatumomab. Therapeutic removal of Tregs may convert blinatumomab non-responders to responders.
Newly Detected Solid Nodules at Incidence CT Lung Cancer Screening Rounds : Occurrence and Lung Cancer Probability
Authors: Joan E. Walter, Marjolein A. Heuvelmans, Geertruida H. De Bock, Pim A. De Jong, Rozemarijn Vliegenthart, Matthijs Oudkerk
Journal: Journal of Thoracic Oncology (2015)
Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.
Authors: Donna E. Reece, Faraz Zaman, Young Trieu, Giovanni Piza Rodriguez, Bruno Teixeira, Kim Yoong, Fernando Camacho, Richard K Plante
Journal: Blood (2009)
Abstract 252: Endocardial Cushion-derived Cardiovascular Progenitor Cells
Authors: Raymond Truong
Journal: Circulation Research (2013)

Introduction: Regenerative therapies utilizing cardiac progenitor cells (CPCs) derived from human embryonic stem cells (hESC) have the potential to regenerate damaged myocardium post-myocardial infarctions. Previous studies have identified multipotent progenitors localized in the endocardial cushions of the developing mouse heart. Recent data in mice have also shown that the loss of a single transcription factor, Scl, enabled robust cardiomyogenic potential in these progenitor cells. Further analyses have delineated that these progenitors can be identified by co-expression of CD31 and PDGFRα. Recapitulation of this phenotypic progenitor cell from hESCs may have potential for clinical regenerative therapies. Hypothesis: We hypothesize that CD31 + /PDGFRα + cells sorted from wild type mouse and human fetal heart tissue possess nascent cardiomyogenic potential. In addition, we believe that close mimicry of the in vivo developmental process of cushion formation would generate a hESC-derived CPC expressing CD31 and PDGFRα. Methods: CD31 + /PDGFRα + cells sorted from wild type mouse heart and human fetal heart are plated in cardiac differentiation medium. Through a stage-specific differentiation protocol, hESCs are first differentiated into mesodermal progenitor cells, which then are sorted for the endothelial marker CD31. Under cardiac culture conditions, these CD31 + cells express the CPC marker PDGFRα. The CD31 + /PDGFRα + cells are then isolated and characterized through quantitative PCR, immunostaining, and functional assays. Results: Wild type mouse heart CD31 + /PDGFRα + cells, when isolated at E14.5 and plated in cardiac differentiation medium, develop beating colonies. In addition, CD31 + /PDGFRα + cells are present in human fetal hearts. Moreover, hESC-derived CD31 + /PDGFRα + cells, when cultured in cardiac medium, show increased expression of cardiomyogenic markers. Conclusions: We conclude that endogenous hESC-derived CD31 + /PDGFRα + cells have cardiogenic potential through in vitro differentiation, exhibited by their expression of cardiomyocyte characteristics and ability to beat. These cells may represent putative endocardial cushion-derived CPCs.